| Host |
Mouse |
| Clone |
6F-H2 |
| Format |
Ready-to-use |
| Method |
F, P |
| Pretreatment |
EDTA |
| Positive control |
Wilm´s tumor |
| Dilution |
- |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasm, nucleus |
WT1 (Wilm's Tumor Protein-1)
|
Diagnostic Biosystems |
6F-H2 |
6 ml |
Ready-to-use |
CE/IVD |
PDM177 |
-
|
| Host |
Mouse |
| Clone |
6F-H2 |
| Format |
Ready-to-use |
| Method |
F, P |
| Pretreatment |
EDTA |
| Positive control |
Wilm´s tumor |
| Dilution |
- |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasm, nucleus |
WT1 (Wilm's Tumor Protein-1)
|
Diagnostic Biosystems |
6F-H2 |
25 ml |
Ready-to-use |
CE/IVD |
PDM177-25 |
-
|
| Host |
Mouse |
| Clone |
rWT1/857 |
| Format |
concentrate |
| Method |
P |
| Pretreatment |
Citrate o EDTA |
| Positive control |
Wilms' tumor, mesothelioma, or normal kidney |
| Dilution |
1:100 |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant full-length human WT1 protein |
| Localization |
Nuclear and cytoplasmic |
WT1 [rWT1/857]
|
Biocare Medical |
rWT1/857 |
0.1 ml |
concentrate |
CE/IVD |
ACI3238A |
-
|
| Host |
Mouse |
| Clone |
rWT1/857 |
| Format |
concentrate |
| Method |
P |
| Pretreatment |
Citrate o EDTA |
| Positive control |
Wilms' tumor, mesothelioma, or normal kidney |
| Dilution |
1:100 |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant full-length human WT1 protein |
| Localization |
Nuclear and cytoplasmic |
WT1 [rWT1/857]
|
Biocare Medical |
rWT1/857 |
1ml |
concentrate |
CE/IVD |
ACI3238C |
-
|
| Host |
Mouse |
| Clone |
rWT1/857 |
| Format |
ready-to-use |
| Method |
P |
| Pretreatment |
Citrate o EDTA |
| Positive control |
Wilms' tumor, mesothelioma, or normal kidney |
| Dilution |
--- |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant full-length human WT1 protein |
| Localization |
Nuclear and cytoplasmic |
WT1 [rWT1/857]
|
Biocare Medical |
rWT1/857 |
6ml |
ready-to-use |
CE/IVD |
API3238AA |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM97 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Tonsil, CLL/SLL. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant fragment of human ZAP70 protein (around aa247-382) |
| Localization |
Cytoplasm |
ZAP-70
|
Zeta Corporation |
ZM97 |
1 ml |
Concentrate |
CE/IVD |
Z2407ML |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM97 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Tonsil, CLL/SLL. |
| Dilution |
- |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant fragment of human ZAP70 protein (around aa247-382) |
| Localization |
Cytoplasm |
ZAP-70
|
Zeta Corporation |
ZM97 |
7 ml |
Ready-to-use |
CE/IVD |
Z2407MP |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM97 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Tonsil, CLL/SLL. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant fragment of human ZAP70 protein (around aa247-382) |
| Localization |
Cytoplasm |
ZAP-70
|
Zeta Corporation |
ZM97 |
0.5 ml |
Concentrate |
CE/IVD |
Z2407MS |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM97 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Tonsil, CLL/SLL. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant fragment of human ZAP70 protein (around aa247-382) |
| Localization |
Cytoplasm |
ZAP-70
|
Zeta Corporation |
ZM97 |
0.1 ml |
Concentrate |
CE/IVD |
Z2407MT |
-
|